GASK1B-AS1: A Potential Drug Target and Biomarker (G285505)

Target Name: GASK1B-AS1

NCBI ID: G285505

GASK1B-AS1

GASK1B-AS1: A Potential Drug Target and Biomarker

GASK1B-AS1, also known as GASK1B-AS1 variant 1, is a gene that encodes a protein known as GASK1B-AS1. GASK1B is a key regulator of the inlet vesicle transport pathway, a process that is essential for the formation and maintenance of the endosomal system. The GASK1B-AS1 gene has been associated with a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

Recent studies have identified GASK1B-AS1 as a potential drug target and biomarker for a variety of neurological disorders. In addition to its association with neurodegenerative diseases, GASK1B-AS1 has also been shown to be involved in a number of other processes that are relevant to disease, including the development and progression of cancer, neuroinflammation, and neurotransmission.

GASK1B-AS1 functions as a negative regulator of the microtubule dynamics that are involved in the transport of intracellular vesicles, including the endosomal system. It does this by interact with the protein tau, which is a key component of the microtubules. By interacting with tau , GASK1B-AS1 has been shown to regulate the assembly and disassembly of microtubules, as well as the transport of intracellular vesicles.

In addition to its role in regulating microtubule dynamics, GASK1B-AS1 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and progression of cancer. For example, GASK1B-AS1 has been shown to interact with the protein PD-L1, which is a negative regulator of the T-cell receptor signaling pathway. This interaction between GASK1B-AS1 and PD-L1 has been shown to promote the development and progression of cancer by inhibiting the negative regulatory role of PD -L1.

GASK1B-AS1 has also been shown to be involved in the regulation of neuroinflammation, a process that is thought to play a role in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, GASK1B-AS1 has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of neuroinflammation. This interaction between GASK1B-AS1 and NF-kappa-B has been shown to contribute to the development and progression of neuroinflammation by promoting the production of pro- inflammatory cytokines.

Finally, GASK1B-AS1 has also been shown to play a role in the regulation of neurotransmission, a process that is involved in the transmission of signals from the brain to the rest of the body. For example, GASK1B-AS1 has been shown to interact with the protein synaptophysin, which is involved in the release of neurotransmitter from synapses. This interaction between GASK1B-AS1 and synaptophysin has been shown to contribute to the regulation of neurotransmission by promoting the release of neurotransmitter.

In conclusion, GASK1B-AS1 is a gene that has been shown to be involved in a number of processes that are relevant to the development and progression of neurological and psychiatric disorders. Its function as a negative regulator of microtubule dynamics, its involvement in the regulation of cellular signaling pathways, its role in the regulation of neuroinflammation, and its involvement in the regulation of neurotransmission suggest that GASK1B-AS1 may be a valuable drug target and biomarker for a variety of neurological disorders. Further research is needed to fully understand the role of GASK1B-AS1 in disease and to develop effective treatments.

Protein Name: GASK1B Antisense RNA 1

The "GASK1B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GASK1B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets